Antagonizing ClpP: A New Power Play in Targeted Therapy for AML

Karilyn Larkin; John C Byrd

doi:10.1016/j.ccell.2015.05.013

Antagonizing ClpP: A New Power Play in Targeted Therapy for AML

Cancer Cell. 2015 Jun 8;27(6):747-9. doi: 10.1016/j.ccell.2015.05.013.

Authors

Karilyn Larkin¹, John C Byrd²

Affiliations

¹ Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA.
² Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, B302 Starling-Loving Hall, 320 West 10(th) Avenue, Columbus, OH 43210, USA. Electronic address: john.byrd@osumc.edu.

PMID: 26058072
DOI: 10.1016/j.ccell.2015.05.013

Abstract

In this issue of Cancer Cell, Cole and colleagues report a non-mutant mitochondrial protein (ClpP) that is overexpressed in a wide range of acute myeloid leukemia (AML) cases, but not in normal hematopoietic precursors. This finding suggests a potentially unique therapeutic targeting opportunity for this difficult-to-treat disease.

Publication types

Comment

MeSH terms

Animals
Endopeptidase Clp / antagonists & inhibitors*
Enzyme Inhibitors / pharmacology*
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / enzymology*
Male

Substances

Enzyme Inhibitors
Endopeptidase Clp